Skip to content

We can’t see our death ahead….. But

our infected genome can…..

Femto Lab© sees your infected genome in dried saliva…….

Growing Genome lab with more than 4 international and national awards

Fixed Price Projects

Receive on time

Fast work turnaround

Our Services

Our tests have been created from our continuous non-stop R&D since before the official running of the DNA business in 2006, covering cancers, Alzheimer’s, SLE, and etc.

Who should need these tests?

1.  Healthy individual either with or without a family history of cancers. (5% of cancer patients are with familial cancer syndromes, 95% are from lifestyle and environment)

2. Cured-cancer patients who are afraid of recurrence.

3. Any cancer patient who needs to know whether he/she resists current standard medication.

4. Any cancer patient whose clinician/oncologist needs to prescribe a targeted drug(s).

5. Any individual or cancer patient who needs to know whether he/she gets an infection at the DNA levels.

6. Any cancer patient who needs precise personalized treatment.

Detection of cancer in your infected genome

Know Cause… Know Cure

A case study

A 48-year-old male patient had late-stage IV lymphoma. After courses of complete chemotherapy and radiation therapy, his doctor allowed him to seek treatment elsewhere. He and his family decided to take the Plasma p53Oncobiomeฉ test. We found some worm and bacterial DNA insertions in his DNA. These organisms were previously reported as causal-related or opportunistic pathogens in lymphoma. These species were Schistosoma mansoni (blood fluke), Strongyloides stercoralis (threadworm), and some bacteria such as Fusobacterium nucleatum (periodontal infection). By eliminating pathogenic bacteria using probiotics and getting rid of the parasites using both chemical drugs and herbal extracts, this patient has now been staying well with his family for two years.

Detection of infertility in your infected genome

Their Plasma/Saliva p53Microbiome helps detect infections that can lead to infertility and cancer. 

Infertility affects an estimated 48 million women, with the highest numbers concentrated in regions that include South Asia and Central Asia. WHO reported that over 10% of women are inflicted – women who have tried unsuccessfully, and have remained in a stable relationship for five years or more. 

Infertility is defined as the failure to achieve a clinical pregnancy after 12 months of regular unprotected sexual intercourse. There are two types of infertility: Primary and Secondary. “Primary Infertility” is infertility in a couple who have never had a child. “Secondary infertility” is failure to conceive following a previous pregnancy. Besides, some couples are defined as “Subfertility”. For these couples, the possibility of conceiving naturally exists, but takes longer than average. 

In most cases, assistive technologies such as in-vitro fertilization (IVF) with or without Intra Cytoplasmic Sperm Injection (ICSI) are used to assist couples affected by infertility and subfertility. However, the success rates of conception using these technologies are still low. Many infertile couples thus inevitably encounter the physical, psychosocial, and financial burden of ART.

Femto Research Group, a self-funding research-based DNA laboratory company in Thailand, is unique in its study of infertility causes. Femto has expanded Plasma/Saliva p53Microbiome in identifying infections found in infertile couples genomes.

Asymptomatic infection is a major contributor to infertility, and male infections can impact sperm quality and function. Bacterial infections can cause pathologies such as chronic endometritis (CE), and pelvic inflammatory disease (PID) in female infertility. CE can cause recurrent implantation failure, recurrent early pregnancy loss (REPL), and fetal demise. 

In Assistive Reproductive Technologies (ART), PID may decrease implantation rates, increase early miscarriages, and may also increase the risk of preterm labor. Parasites and fungi infections can damage the ability to conceive, ectopic pregnancy, or pregnancy with an undesired course. Chronic viral infections can infect sperm and are considered a risk factor in male infertility.

Femto Lab has successfully developed a reliable, never-before-existing diagnostic innovation to detect/identify asymptomatic infections (at the genus, species, and strains) in human infertile genomes. Using their DBS/DSS p53Microbiome innovations allows them to look for infections and use precisely suitable chemical/herbal/natural treatments to help improve the success rates of ART in infertile couples, reduce cancer from their infected genomes, and lessen the risk of ovarian cancer from repeated IVF/ART cycles using high-dose ovulation-stimulating drugs.

With innovations developed to improve human health via the microbiome-based diagnosis, p53Microbiome in couples predicts the accurate outcome of IVF/ART while keeping on track with “Precision Health and Precision Medicine”, their global personalized healthcare goal.

https://healthcareasiamagazine.com/co-written-partner/event-news/femto-research-group-co-ltd-snags-service-innovation-year-thailand-healthcare-asia-2021

We are driven by values

Featured Work:

Learn More

Our Achievements

2022 Healthcare Asia Awards

Femto Research Group Co., Ltd.-Thailand bags the Service Innovation of the Year Trophy at the 2022 Healthcare Asia Awards
Their innovative direct-to-customer cancer detection kit served home patients via postage.

https://healthcareasiamagazine.com/videos/healthcare-asia-awards-2022-winner-femto-research-group-co-ltd

2021 HEALTHCARE ASIA AWARDS WINNER: FEMTO RESEARCH GROUP

Femto Research Group bagged its fourth Service Innovation of the Year – Thailand award at this year’s Healthcare Asia Awards.

Hear from their Founder, CEO, R&D Director, Dr. Klaiupsorn S. Pongrapeeporn, as she talks about their winning initiatives and future plans for clients and customers.

https://healthcareasiamagazine.com/videos/healthcare-asia-awards-2021-winner-femto-reasearch-group

2020 Healthcare Asia Awards Winner: Femto Research Group Co.,Ltd.

Dr. Klaiupsorn S. Pongrapeeporn of Femto Research Group Co.,Ltd. talks about their recent achievement as a winner of Healthcare Asia Awards 2020. Femto Research Group Co.,Ltd. bagged the Service Innovation of the Year for the third time for Thailand.

https://healthcareasiamagazine.com/co-written-partner/more-news/femto-research-grabs-service-innovation-year-healthcare-asia-awards

2019 Healthcare Asia Awards

Breakthrough Innovation “DBS” : a game changer in the field of cancer research….

https://vimeo.com/339091765

2018 HEALTH CARE ASIA AWARD

Femto Research Group Co., Ltd.-Thailand bags the Healthcare Asia Awards 2018 for Service Innovation of the Year

The genetics firm has progressed in technologies for early cancer detection

For more than a decade, Femto Research Group’s research-based laboratory has focused on research and development (R&D) that aims to provide innovative services. These services are expected to benefit the healthcare community while attempting to comply with the goals announced by the HGP and Human Microbiome Project (HMP). In Asia, Femto Research Group’s unique Plasma DNA tests are available only at Femto Lab. On the other hand, the unique “Plasma Microbiome” test is now commercially available only at Femto Lab at the global level.

https://healthcareasiamagazine.com/healthcare/more-news/femto-research-group-co-ltd-thailand-bags-healthcare-asia-awards-2018-service-i

September 2011, NSTDA Investors’ Day, Ministry of Science and Technology.

Let’s work together for your
better health